The first antiangiogenesis drug bevacizumab (a monoclonal antibody for VEGFA) was launched in 2004 and many small molecules that inhibit the activity and signaling cascade of VEGF receptors (VEGFRs) have been developed and approved by the US FDA for the treatment of various types of cancer [12]. This evidence concerns the gene VEGFA and cancer.